These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 6299747)
1. Counting the costs of cancer therapy. Friedlander ML; Tattersall MH Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1237-41. PubMed ID: 6299747 [TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy in solid tumours. A review of published data in selected tumours with a commentary. Antman KH; Souhami RL Ann Oncol; 1993; 4 Suppl 1():29-44. PubMed ID: 8393339 [No Abstract] [Full Text] [Related]
3. The pharmacoeconomics of cancer therapies. Bishop JF; Macarounas-Kirchman K Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279 [TBL] [Abstract][Full Text] [Related]
4. [High-dose chemotherapy as a strategy to overcome drug resistance in solid tumors]. Selle F; Gligorov J; Soares DG; Lotz JP Bull Cancer; 2016 Oct; 103(10):861-868. PubMed ID: 27641463 [TBL] [Abstract][Full Text] [Related]
5. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective. Sagar B; Lin YS; Castel LD J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874 [TBL] [Abstract][Full Text] [Related]
6. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer. Khan ZM; Rascati KL; Koeller JM Pharmacoeconomics; 1999 Jul; 16(1):43-57. PubMed ID: 10539121 [TBL] [Abstract][Full Text] [Related]
7. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Doyle JJ; Dezii CM; Sadana A Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Evans WK; Will BP; Berthelot JM; Wolfson MC Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481 [TBL] [Abstract][Full Text] [Related]
11. Interpreting the economic literature in oncology. Grusenmeyer PA; Wong YN J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940 [TBL] [Abstract][Full Text] [Related]
12. Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer. Hoskins PJ; Fung-Kee-Fung M; Miller D; Gotlieb W J Clin Oncol; 2015 May; 33(14):1539-42. PubMed ID: 25847922 [No Abstract] [Full Text] [Related]
13. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France. Hurtaud A; Donnadieu A; Escalup L; Cottu PH; Baffert S Breast; 2016 Dec; 30():73-79. PubMed ID: 27639032 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer. Drummond M; Davies L Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594 [TBL] [Abstract][Full Text] [Related]
16. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eskens FA; Sleijfer S Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679 [TBL] [Abstract][Full Text] [Related]
17. Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group. Loehrer PJ Semin Oncol; 1992 Dec; 19(6 Suppl 14):48-52. PubMed ID: 1336900 [TBL] [Abstract][Full Text] [Related]